Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines
Remifentanil is a potent ultra-short acting μ-opioid analgesic drug, frequently used in anaesthesia due to its favorable pharmacodynamic and pharmacokinetic profile. It may be associated with the occurrence of hyperalgesia. Preclinical studies suggest a potential role of microglia, although the mole...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund
2023-02-01
|
| Series: | EXCLI Journal : Experimental and Clinical Sciences |
| Subjects: | |
| Online Access: | https://www.excli.de/index.php/excli/article/view/5667 |
| _version_ | 1797843525277057024 |
|---|---|
| author | Cinzia Dello Russo Natalia Cappoli Elisabetta Tabolacci Liliana Sollazzi Pierluigi Navarra Paola Aceto |
| author_facet | Cinzia Dello Russo Natalia Cappoli Elisabetta Tabolacci Liliana Sollazzi Pierluigi Navarra Paola Aceto |
| author_sort | Cinzia Dello Russo |
| collection | DOAJ |
| description | Remifentanil is a potent ultra-short acting μ-opioid analgesic drug, frequently used in anaesthesia due to its favorable pharmacodynamic and pharmacokinetic profile. It may be associated with the occurrence of hyperalgesia. Preclinical studies suggest a potential role of microglia, although the molecular mechanisms have not been fully elucidated. Considering the role of microglia in brain inflammation and the relevant differences among species, the effects of remifentanil were studied on the human microglial C20 cells. The drug was tested at clinically relevant concentrations under basal and inflammatory conditions. In the C20 cells, the expression and secretion of interleukin 6, interleukin 8 and the monocyte chemotactic protein 1 were rapidly induced by a mixture of pro-inflammatory cytokines. This stimulatory effect was sustained up to 24 h. Remifentanil did not exert any toxic effect nor modify the production of these inflammatory mediators, thus suggesting the lack of direct immune modulatory actions on human microglia. |
| first_indexed | 2024-04-09T17:06:39Z |
| format | Article |
| id | doaj.art-9e67f52793c34d66bbea81e20a749645 |
| institution | Directory Open Access Journal |
| issn | 1611-2156 |
| language | English |
| last_indexed | 2024-04-09T17:06:39Z |
| publishDate | 2023-02-01 |
| publisher | IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund |
| record_format | Article |
| series | EXCLI Journal : Experimental and Clinical Sciences |
| spelling | doaj.art-9e67f52793c34d66bbea81e20a7496452023-04-20T12:35:35ZengIfADo - Leibniz Research Centre for Working Environment and Human Factors, DortmundEXCLI Journal : Experimental and Clinical Sciences1611-21562023-02-012229530910.17179/excli2022-56675106Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokinesCinzia Dello Russo0https://orcid.org/0000-0002-2538-3832Natalia Cappoli1https://orcid.org/0000-0002-4705-3340Elisabetta Tabolacci2https://orcid.org/0000-0002-4707-2242Liliana Sollazzi3https://orcid.org/0000-0002-2973-6236Pierluigi Navarra4https://orcid.org/0000-0002-4424-650XPaola Aceto5https://orcid.org/0000-0002-0228-0603Dipartimento di Sicurezza e Bioetica, Sezione di Farmacologia, Università Cattolica Del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Department of Pharmacology & Therapeutics, Institute of Systems Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United KingdomDipartimento di Sicurezza e Bioetica, Sezione di Farmacologia, Università Cattolica Del Sacro Cuore, L.go F Vito 1, 00168 Rome, Italy; E-mail: natalia.cappoli@unicatt.itDipartimento di Scienze Della Vita e Sanità Pubblica, Sezione di Medicina Genomica, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyDipartimento di Scienze dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, ItalyDipartimento di Sicurezza e Bioetica, Sezione di Farmacologia, Università Cattolica Del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyDipartimento di Scienze dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, ItalyRemifentanil is a potent ultra-short acting μ-opioid analgesic drug, frequently used in anaesthesia due to its favorable pharmacodynamic and pharmacokinetic profile. It may be associated with the occurrence of hyperalgesia. Preclinical studies suggest a potential role of microglia, although the molecular mechanisms have not been fully elucidated. Considering the role of microglia in brain inflammation and the relevant differences among species, the effects of remifentanil were studied on the human microglial C20 cells. The drug was tested at clinically relevant concentrations under basal and inflammatory conditions. In the C20 cells, the expression and secretion of interleukin 6, interleukin 8 and the monocyte chemotactic protein 1 were rapidly induced by a mixture of pro-inflammatory cytokines. This stimulatory effect was sustained up to 24 h. Remifentanil did not exert any toxic effect nor modify the production of these inflammatory mediators, thus suggesting the lack of direct immune modulatory actions on human microglia.https://www.excli.de/index.php/excli/article/view/5667human microgliaremifentanilhyperalgesiainterleukin-6interleukin-8monocyte chemotactic protein 1 |
| spellingShingle | Cinzia Dello Russo Natalia Cappoli Elisabetta Tabolacci Liliana Sollazzi Pierluigi Navarra Paola Aceto Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines EXCLI Journal : Experimental and Clinical Sciences human microglia remifentanil hyperalgesia interleukin-6 interleukin-8 monocyte chemotactic protein 1 |
| title | Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines |
| title_full | Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines |
| title_fullStr | Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines |
| title_full_unstemmed | Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines |
| title_short | Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines |
| title_sort | remifentanil does not affect human microglial immune activation in response to pro inflammatory cytokines |
| topic | human microglia remifentanil hyperalgesia interleukin-6 interleukin-8 monocyte chemotactic protein 1 |
| url | https://www.excli.de/index.php/excli/article/view/5667 |
| work_keys_str_mv | AT cinziadellorusso remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines AT nataliacappoli remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines AT elisabettatabolacci remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines AT lilianasollazzi remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines AT pierluiginavarra remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines AT paolaaceto remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines |